3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Completed
9
Terminated
5
Unknown
2
Active not recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Other hematologic neoplasm
1
Conditions
Pancreatic Neoplasms
42
Urinary Bladder Neoplasms
18
Carcinoma, Non-Small-Cell Lung
18
Ovarian Neoplasms
11
Triple Negative Breast Neoplasms
10
Neoplasm Metastasis
10
Nasopharyngeal Carcinoma
10
Breast Neoplasms
10
Lymphoma, Large B-Cell, Diffuse
9
Fallopian Tube Neoplasms
9
Lung Neoplasms
8
Carcinoma, Transitional Cell
8
Biliary Tract Neoplasms
7
Recurrence
6
Gallbladder Neoplasms
6
Neoplasms
5
Cholangiocarcinoma
5
Non-Muscle Invasive Bladder Neoplasms
4
Colorectal Neoplasms
4
Urothelial Cancer
3
Stomach Neoplasms
3
Melanoma
3
Lymphoma, Non-Hodgkin
3
Lymphoma
3
Carcinoma
3
Uterine Cervical Neoplasms
2
Urethral Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Pancreatic Adenocarcinoma
2
Non Small Cell Lung Carcinoma NSCLC
2
Interventions
Rituximab
25
Lenalidomide
20
Cyclophosphamide
18
obinutuzumab
8
Vincristine
8
Doxorubicin
8
Prednisone
7
Bendamustine Hydrochloride
7
tazemetostat
6
ibrutinib
6
Biopsy
6
venetoclax
5
pembrolizumab
5
fludarabine
5
Specimen Handling
5
CT-P10
5
fludarabine phosphate
4
R-CHOP protocol
4
Peripheral Blood Stem Cell Transplantation
4
Nivolumab
4
Magnetic Resonance Spectroscopy
4
Prednisolone
3
Etoposide
3
tocilizumab
2
copanlisib
2
axicabtagene ciloleucel
2
atezolizumab
2
acalabrutinib
2
abexinostat
2
Whole-Body Irradiation
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Active not recruiting
×
Lymphoma, Follicular
×
Gemcitabine
×
Clear all
NCT04542824
2026-06-02
EPCOREâ„¢ NHL-3
Genmab
Phase 1/2
Active not recruiting
78 enrolled
NCT04663347
2026-06-02
EPCOREâ„¢ NHL-2
Genmab
Phase 1/2
Active not recruiting
543 enrolled